Edema, Nephrotic Syndrome
Conditions
Keywords
Edema, Nephrotic syndrome, Acetazolamide, Furosemide
Brief summary
The purpose of this study is to determine whether using furosemide following acetazolamide is effective in treating refractory edema associated with nephrotic syndrome.
Detailed description
Edema is referred to increase in interstitial fluid that is clinically evident. The main causes of generalized edema are heart failure, renal failure, nephrotic syndrome, glomerulonephritis and chronic liver failure. In some cases, edema is treated by management of the underlying disease. However, in some other cases edema may persist and become more severe that needs adjuvant treatments. Because use of diuretics such as furosemide and hydrochlorothiazide is not completely effective in treating severe refractory edema, use of some other diuretics is also recommended. In this double-blind clinical trial, weight and some lab data including blood urea nitrogen, serum creatinine, serum sodium, serum potassium, serum albumin, urine sodium, urine potassium, 24-hour urine volume, 24-hour urine protein and 24-hour urine creatinine of 20 random adult patients with nephrotic syndrome who have refractory edema and GFR\>60 ml/min/1.73m2 and are referred to nephrology clinic of Shiraz University of Medical Sciences will be measured; the patients should not have hypokalemia and other causes of edema such as heart failure or cirrhosis. Then the patients are divided into 2 groups with 10 members in each. The first group will be prescribed 40 mg of furosemide and 50 mg of hydrochlorothiazide and the second one will receive 250 mg of acetazolamide and 50 mg of hydrochlorothiazide daily for 1 week. Then, weight and mentioned lab data will be measured again. After that, all the patients will have 40 mg of furosemide daily for 2 weeks. Then, weight and mentioned lab data will be measured for one more time.
Interventions
DRUGAcetazolamide and Hydrochlorothiazide Followed by Furosemide
DRUGFurosemide and Hydrochlorothiazide Followed by Furosemide
Sponsors
Shiraz University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Having refractory edema due to nephrotic syndrome 2. Having GFR\>60 ml/min/1.73m2 3. Being able to come for weekly visit 4. Having the minimum age of 18 years 5. Signing the informed consent form
Exclusion criteria
1. Hypokalemia 2. Pregnancy 3. Renal transplant 4. active malignancy or infection 5. acidosis 6. Using NSAIDs 7. Having another causes of edema including liver cirrhosis, heart failure 8. Neurologic or psychiatric problem hindering adherence to the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in weight at the end of third week | Baseline and at the end of the third week |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in systolic and diastolic blood pressure at the end of third week | Baseline and at the end of the third week |
| Change from baseline in serum sodium at the end of third week | Baseline and at the end of the third week |
| Change from baseline in serum potassium at the end of third week | Baseline and at the end of the third week |
| Change from baseline in blood urea nitrogen at the end of third week | Baseline and at the end of the third week |
| Change from baseline in serum creatinine at the end of third week | At the start and at the end of the third week |
| Change from baseline in serum albumin at the end of third week | Baseline and at the end of the third week |
| Change from baseline in urine sodium at the end of third week | Baseline and at the end of the third week |
| Change from baseline in urine potassium at the end of third week | Baseline and at the end of the third week |
| Change from baseline in 24-hour urine volume at the end of third week | Baseline and at the end of the third week |
| Change from baseline in 24-hour urine creatinine at the end of third week | Baseline and at the end of the third week |
| Change from baseline in 24-hour urine protein at the end of third week | Baseline and at the end of the third week |
Outcome results
None listed